5 results about "Immunosuppressive treatment" patented technology

This invention discloses a myocarditis treatment prediction system integrating Transformer and causal reinforcement learning, comprising a data preprocessing module, a temporal encoding module, a causal decision-making module, and an interpretation regularization module. The data preprocessing module transforms multimodal clinical data into equally spaced state representation sequences; the temporal encoding module extracts global temporal dependencies through the multi-head self-attention mechanism of a Transformer encoder, outputting an abstract state vector; the causal decision-making module uses the abstract state vector as input to construct a Markov decision process, employs offline strategies to evaluate and estimate the expected clinical benefits of different intervention timings, and outputs individualized intervention recommendations and confidence levels through policy gradient optimization. This invention can capture the dynamic evolution of myocarditis disease under limited case conditions, assess the causal effects of different intervention strategies without real clinical trials, and provides a transparent and interpretable decision-making process, effectively assisting clinicians in identifying the optimal timing for immunosuppressive therapy.

Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

This specification provides methods and uses of treatment involving the administration of voclosporine to subjects who have previously received a calcineurin inhibitor (CNI), such as cyclosporine, tacrolimus, or derivatives thereof, for immunosuppression. In some embodiments, the methods and uses relate to selecting subjects who have previously received a CNI, such as cyclosporine, tacrolimus, or derivatives thereof, for immunosuppression, for the administration of voclosporine. In some embodiments, the methods and uses relate to treating or mitigating adverse effects that may be associated with immunosuppression using a CNI, such as cyclosporine, tacrolimus, or derivatives thereof. In some embodiments, the methods and uses include administering a therapeutically effective dose of voclosporine to the selected subjects.

The present invention relates to methods for monitoring potential indications of allogeneic organ rejection by monitoring transplanted hair follicles from the same donor of a transplanted organ, and for performing or modifying immunosuppressive therapy to ameliorate or prevent the occurrence of acute or chronic organ rejection. The methods of the invention may also be used to select candidate allogeneic solid organ donors for recipients, as well as to improve the occurrence of acute rejection of transplanted allogeneic solid organs, such as kidneys.

The invention discloses a fluorescent quantitative detection kit for positioning a transplanted heart injury tissue source. The fluorescent quantitative detection kit specifically comprises the following steps: S1, collecting and treating a serum sample; s2, carrying out RNA kit extraction by adopting serum or plasma; s3, gDNA removal and reverse transcription are carried out; s4, carrying out quantitative PCR (Polymerase Chain Reaction) detection by adopting an SYBR Green method; and S5, data analysis. The invention relates to the technical field of medical diagnosis. According to the fluorescent quantitative detection kit for positioning the injured tissue source of the transplanted heart, accurate positioning of the injured tissue source of the heart is realized through multi-index joint detection, an important basis is provided for clinical individualized immunosuppression treatment, and the occurrence rate and the death rate of complications after heart transplantation are remarkably reduced; the kit can be used for accurately detecting the marker derived from the damaged heart tissue.